BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from ...